Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ia, Open Label, Single Ascending Dose Study to Assess the Safety and Tolerability of KSI 301 in Patients with Diabetic Macular Oedema

Next Previous
Trial Profile

A Phase Ia, Open Label, Single Ascending Dose Study to Assess the Safety and Tolerability of KSI 301 in Patients with Diabetic Macular Oedema

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 14 Aug 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs KSI 301 (Primary)
  • Indications Diabetic macular oedema
  • Focus Adverse reactions; First in man
  • Sponsors Kodiak Sciences

    • Most Recent Events

    • 14 Aug 2019 According to a Kodiak Sciences media release, data presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2019 Annual Meeting highlighted the final 12-week results of the Phase 1a clinical study of KSI-301 with sustained responses observed after a single dose of KSI-301, measured as improvement from baseline in vision, retinal anatomy, or both.
    • 25 Apr 2019 According to a Kodiak Sciences media release, the data from this study will be made at the Association for Research in Vision and Ophthalmology (ARVO) 2019 Annual Meeting.
    • 28 Mar 2019 According to a Kodiak Sciences media release, the data from this study were presented at the Angiogenesis, Exudation, and Degeneration 2019 medical meeting on February 9, 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top